Disruptive medical technology – “paradigm buster” entering market

1 Last

HC Trader

13,496 Posts.

325

30/01/17

15:55

Post #: 22221761

Column 1

0
BPH Energy (ASX:BPH) is offering retail and sophisticated investors exposure to Cortical Dynamics Ltd (Cortical), an unlisted Australian medical device technology company currently marketing an industry disruptive brain function monitor which has been independently described as:

Column 1

0
“A paradigm busting technology from an Australian based device house that really gives a significant advantage in this space”[1].

Column 1

0
The Brain Anaesthetic Response (BAR) monitor assists anaesthetists to ensure patients remain optimally anaesthetized during surgery. Its competitive advantage has been recognised by leading world experts in anaesthesia. Cortical has received both TGA approval and the CE mark and has now commenced its sales campaign. Incorporated in 2004, Cortical has focused developed and is now commercialising a brain monitoring technology developed at Swinburne University of Technology in Melbourne. Professor David Liley led research resulting in the invention of a new methodology which uses a complex mathematical algorithm to quantify important physiological features of higher brain function in real time. According to Cortical: The core technology is based on real time analysis of the patient’s brain electrical activity, electroencephalograph (EEG), using a proprietary algorithm based on a mathematically and physiologically detailed understanding of the brain’s rhythmic electrical activity. Until now, there has been no reliable way to monitor consciousness in a patient’s brain during anaesthesia. Cortical has achieved this outcome for the first time. In 2012, the global brain monitoring market equated to $1.08BN and is poised to grow at a CAGR of 8.6% to reach $1.63BN by next year. Cortical plans to IPO this year. The company has received industry recognition and awards in the areas of technology, pharma, manufacturing and more. BPH is a significant investor in Cortical, and has the right to exercise its option to take over 15% of the company pre-IPO. An analysis of IPOs on ASX over the last 8 years to end 2016 has shown:

Average first day premium (from the issue price) of 18.79 %

Average premium from list price after three months of 25.48% [2]

Could this company achieve the average on ASX premium from listing price of 25.48% * and if so, what impact will this have on micro-cap BPH with its market cap of just $2.9M?Retail investors can gain exposure to Cortical via BPH. Sophisticated investors may take up an offer to invest directly in Cortical shares pre-IPO (see below).

Column 1

0

Column 1

0

Column 1

0
Click here to learn more

[/LEFT][/table][/table]

Column 1

0
BPH has dual medical technology and energy exposures. Potential investors should read more on the company’s projects and consult their professional advisor before making an investment decision.
www.bphenergy.com.au
Cortical is offering professional, sophisticated and eligible overseas investors the opportunity to subscribe for shares in Cortical on a pre IPO basis. Eligible investors under Section 708 can register here **

Column 1

0

Column 1

0

Column 1

0
Click here to read the full article**

[/LEFT][/table][/table]

Column 1

0
INVESTORS Only Sophisticated Investors can invest in the Cortical pre IPO opportunity as per Section 708 of the Corporations Act 2001 (Cth) HIGH RISK WARNING This investment product is high risk; you should consult with your financial planner or stock broker prior to investing in this opportunity. The information in this email should not be the only trigger for your investment decision. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

	Column 1
0	BPH Energy (ASX:BPH) is offering retail and sophisticated investors exposure to Cortical Dynamics Ltd (Cortical), an unlisted Australian medical device technology company currently marketing an industry disruptive brain function monitor which has been independently described as:

	Column 1
0	“A paradigm busting technology from an Australian based device house that really gives a significant advantage in this space”[1].

	Column 1
0	The Brain Anaesthetic Response (BAR) monitor assists anaesthetists to ensure patients remain optimally anaesthetized during surgery. Its competitive advantage has been recognised by leading world experts in anaesthesia. Cortical has received both TGA approval and the CE mark and has now commenced its sales campaign. Incorporated in 2004, Cortical has focused developed and is now commercialising a brain monitoring technology developed at Swinburne University of Technology in Melbourne. Professor David Liley led research resulting in the invention of a new methodology which uses a complex mathematical algorithm to quantify important physiological features of higher brain function in real time. According to Cortical: The core technology is based on real time analysis of the patient’s brain electrical activity, electroencephalograph (EEG), using a proprietary algorithm based on a mathematically and physiologically detailed understanding of the brain’s rhythmic electrical activity. Until now, there has been no reliable way to monitor consciousness in a patient’s brain during anaesthesia. Cortical has achieved this outcome for the first time. In 2012, the global brain monitoring market equated to $1.08BN and is poised to grow at a CAGR of 8.6% to reach $1.63BN by next year. Cortical plans to IPO this year. The company has received industry recognition and awards in the areas of technology, pharma, manufacturing and more. BPH is a significant investor in Cortical, and has the right to exercise its option to take over 15% of the company pre-IPO. An analysis of IPOs on ASX over the last 8 years to end 2016 has shown: Average first day premium (from the issue price) of 18.79 % Average premium from list price after three months of 25.48% [2] *Could this company achieve the average on ASX premium from listing price of 25.48% and if so, what impact will this have on micro-cap BPH with its market cap of just $2.9M?**Retail investors can gain exposure to Cortical via BPH. Sophisticated investors may take up an offer to invest directly in Cortical shares pre-IPO (see below).

	Column 1
0	BPH has dual medical technology and energy exposures. Potential investors should read more on the company’s projects and consult their professional advisor before making an investment decision. www.bphenergy.com.au Cortical is offering professional, sophisticated and eligible overseas investors the opportunity to subscribe for shares in Cortical on a pre IPO basis. Eligible investors under Section 708 can register here **

	Column 1
0	INVESTORS Only Sophisticated Investors can invest in the Cortical pre IPO opportunity as per Section 708 of the Corporations Act 2001 (Cth) HIGH RISK WARNING This investment product is high risk; you should consult with your financial planner or stock broker prior to investing in this opportunity. The information in this email should not be the only trigger for your investment decision. We strongly recommend you seek professional financial advice whenever making financial investment decisions.